Until we lower drug prices here at home in America, online access
to affordable medication internationally is clearly essential. But what if we
lived in a country where people were no longer able to find safe international
In an ideal world, search algorithms empower consumers to
find the exact information they are looking for on these search engines. In a
recent Google algorithm update (March 2019), which affected the “natural” or
“organic,” non-paid search results, we wonder if there was foul play involved
in which Google was caving in
to Big Pharma. The Electronic Frontier Foundation identified this problem
in 2016, in “How
Big Pharma’s Shadow Regulation Censors the Internet.”
The results at the very top of your Google search are often ads, which are of course paid placement: a different problem.
Those patients searching on Google for information about affording medicine through online pharmacies were significantly disadvantaged by the Google March 2019 Core Update. The reason is that results for PharmacyChecker ‘s verification and pricing information are now much harder to find than they were on March 11th, 2019— a day before the update.
Central to Big Pharma’s lobbying efforts is relying on drug company-funded “nonprofit” groups to sanitize their goals under the veneer of charity. Investigative reporting in Tarbell, a media organization founded by healthcare activist Wendell Potter, shows that drug companies, namely Eli Lilly, successfully lobbied the Obama administration to make Internet companies embrace policies that curtail online access to affordable medication.
These pharma-funded nonprofits engage fellow industry-tied patient groups, the media and people, promoting the idea that rogue online pharmacies and safe international online pharmacies are the same thing. Their message: don’t buy lower-cost medications online from other countries because it’s too dangerous.
There are not many issues you can hear both Republicans and Democrats clapping about in unison, but high drug prices is definitely one of them. Echoing his 2016 campaign, President Trump again proclaimed during his State of the Union address Tuesday night that his administration is determined “to make fixing the injustice of high drug prices one of our top priorities.”
Speeding up the approval of lower-cost generics was noted by Trump as “exciting progress,” but nothing substantial has been done by the Trump administration on drug prices. The appointment of Alex Azar to head the Department of Health and Human Services department was a major disappointment. As president of Eli Lilly USA, Azar oversaw major price hikes on lifeline medications, such as insulin.
Appealing to both his base and popular opinion, President Trump could use his executive authority immediately to more expressly permit Americans to buy medication from international pharmacies.